U.S. Insulin Market

Severe Uniform U.S. Cost Inflation: Severe Patient and Public Harm

U.S. Insulin Market 

  • Uniform massive 5-7-fold U.S. insulin price increases in the decade-plus since Medicare Part D began
  • Despite severe competition among numerous similar products
    • Many insulins on the U.S. market for decades
  • Severe U.S. patient and family harm
    • Diabetes is the highest spending U.S. brand drug category
    • Rising U.S. deaths from unaffordable insulin
    • Diabetics traveling to abroad for cheaper black market insulin

Two Key Whistleblower Insulins": Sanofi's Lantus and Eli Lilly's Humulin

Sanofi's Lantus (long-acting insulin, on U.S. market since 2000)

Eli Lilly’s Humulin (on U.S. market since 1982)

Receive the Latest News

Your email is 100% safe.
Your privacy will be respected.
Something went wrong. Please check your entries and try again.
Scroll to Top